Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Xiaosi Han
Associate Professor
Close
E-mail
xhan@uab.edu
Links
Provider Directory
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Xiaosi Han
Associate Professor
Positions
Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
Associate Professor (P)
,
Neurology
,
School of Medicine
Associate Scientist (C)
,
Center for Clinical and Translational Science (CCTS)
,
General Clinical Research Center
Associate Scientist (C)
,
Comprehensive Neuroscience Center
,
General Clinical Research Center
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2021
Antibody–drug conjugate to treat meningiomas
.
Pharmaceuticals
. 14.
2021
2020
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
.
Neuro-Oncology
. 22:705-717.
2020
2020
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice
.
Cancer Gene Therapy
. 27:246-255.
2020
2019
Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour
.
Journal of Cellular and Molecular Medicine
. 23:6822-6834.
2019
2019
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study
.
PLoS Medicine
. 16.
2019
2019
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis
.
Journal of Neuro-Oncology
. 141:289-301.
2019
2018
Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression
.
Scientific Reports
. 8.
2018
2018
Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1
.
Blood Advances
. 2:2829-2836.
2018
2017
Elevated p53 Activities Restrict Differentiation Potential of MicroRNA-Deficient Pluripotent Stem Cells
.
Stem Cell Reports
. 9:1604-1617.
2017
2017
Canonical microRNAs Enable Differentiation, Protect Against DNA Damage, and Promote Cholesterol Biosynthesis in Neural Stem Cells
2017
2017
Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy.
.
SAGE Open Medical Case Reports
. 5:2050313X17705050.
2017
2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
.
Journal of Neuro-Oncology
. 129:487-494.
2016
2016
Neuronal Wiskott-Aldrich syndrome protein regulates TGF-β1-mediated lung vascular permeability
.
The FASEB Journal
. 30:2557-2569.
2016
2016
Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
.
Neuro-Oncology
. 18:830-839.
2016
2016
Acute disseminated encephalomyelitis presenting as a brainstem encephalitis
.
Clinical Neurology and Neurosurgery
. 143:76-79.
2016
2016
Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses
.
Neuro-Oncology
. 18:227-235.
2016
2015
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas
.
Journal of Neuro-Oncology
. 122:585-593.
2015
2014
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro
.
Journal of Neuro-Oncology
. 118:61-72.
2014
2014
The role of Src family kinases in growth and migration of glioma stem cells
.
International Journal of Oncology
. 45:302-310.
2014
2014
Transcription start site sequence and spacing between the -10 region and the start site affect reiterative transcription-mediated regulation of gene expression in Escherichia coli
.
Journal of Bacteriology
. 196:2912-2920.
2014
2003
The genomic sequence of ectromelia virus, the causative agent of mousepox
.
Virology
. 317:165-186.
2003
2002
Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: Differences in integrin signaling during cell adhesion to osteopontin versus vitronectin
.
Cancer Research
. 62:5336-5343.
2002
Research
Research Overview
Glioblastoma
Low Grade Glioma
Oligodendroglioma
Astrocytome
Principal Investigator On
Private Grant
awarded by
VASCULAR BIOGENICS LTD
Private Grant
awarded by
SUMITOMO PHARMA ONCOLOGY, INC.
Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma
awarded by
National Institute of Neurological Disorders and Stroke/NIH/DHHS
Investigator On
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
awarded by
National Cancer Institute/NIH/DHHS
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)
awarded by
Johns Hopkins University
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
awarded by
Johns Hopkins University
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
awarded by
Johns Hopkins University
A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor
awarded by
Johns Hopkins University
A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma
awarded by
Johns Hopkins University
A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma
awarded by
Memorial Sloan-Kettering Cancer Center
Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress
awarded by
National Cancer Institute/NIH/DHHS
Biosynthetic Metabolic Pathway Regulation of Glioma Growth
awarded by
National Institute of Neurological Disorders and Stroke/NIH/DHHS
Brain Tumor Trials Collaborative Agreement
awarded by
NIH - National Institutes of Health/DHHS
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas
awarded by
Johns Hopkins University
GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM
awarded by
GLOBAL COALITION FOR ADAPTIVE RESEARCH
Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)
awarded by
Dana-Farber Cancer Institute
Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)
awarded by
Dana-Farber Cancer Institute
Modeling Low-grade Gliomas Using Human Pluripotent Stem Cells
awarded by
National Institute of Neurological Disorders and Stroke/NIH/DHHS
NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement
awarded by
National Cancer Institute/NIH/DHHS
NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement
awarded by
NRG ONCOLOGY FOUNDATION
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma
awarded by
Johns Hopkins University
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)
awarded by
Johns Hopkins University
Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma
awarded by
Johns Hopkins University
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
awarded by
Johns Hopkins University
Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
awarded by
Johns Hopkins University
Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma
awarded by
Johns Hopkins University
Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
awarded by
Johns Hopkins University
Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients
awarded by
Johns Hopkins University
Private Grant
awarded by
EMD SERONO
Private Grant
awarded by
Sanofi US Services Inc
Private Grant
awarded by
F.Hoffmann-La Roche Ltd.
Private Grant
awarded by
Sanofi US Services Inc
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
Private Grant
awarded by
NOVOCURE (ISRAEL) LTD
Private Grant
awarded by
ARCHER BIOSCIENCES
Private Grant
awarded by
ARCHER BIOSCIENCES
Private Grant
awarded by
NOVOCURE, INC.
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Private Grant
awarded by
STEMLINE THERAPEUTICS INC
Private Grant
awarded by
ABBVIE INC
Private Grant
awarded by
IMMUNOCELLULAR THERAPEUTICS
Private Grant
awarded by
NATIVIS, INC.
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Private Grant
awarded by
IMMUNOCELLULAR THERAPEUTICS
Private Grant
awarded by
ORBUS THERAPEUTICS, INC.
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Private Grant
awarded by
ABBVIE INC
Private Grant
awarded by
ABBVIE INC
Private Grant
awarded by
SUMITOMO PHARMA ONCOLOGY, INC.
Private Grant
awarded by
BIOMIMETIX JV LLC
Private Grant
awarded by
IN8BIO INC.
Private Grant
awarded by
SERVIER PHARMACEUTICALS LLC
Private Grant
awarded by
OBLATO INC
Private Grant
awarded by
DENOVO BIOPHARMA LLC
Private Grant
awarded by
KARYOPHARM THERAPEUTICS, INC.
Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma
awarded by
Johns Hopkins University
UAB NRG Oncology Master Institution Purchased Service Agreement
awarded by
NRG ONCOLOGY FOUNDATION
UAB NRG Oncology Member Institution Purchased Service Agreement
awarded by
NRG ONCOLOGY FOUNDATION
Background
Education And Training
UAB Hospital, Internship
UAB Hospital, Residency
MD Anderson Cancer Center, Postdoctoral Fellowship
Doctor of Philosophy in Medical Microbiology,
University of Alabama at Birmingham
1998
Doctor of Medicine,
1987
Contact
Full Name
Xiaosi
Han